by Henrik Zetterberg, Erik Mörtberg, Linan Song, Lei Chang, Gail K. Provuncher, Purvish P. Patel, Evan Ferrell, David R. Fournier, Cheuk W. Kan, Todd G. Campbell, Ray Meyer, Andrew J. Rivnak, Brian A. Pink, Kaitlin A. Minnehan, Tomasz Piech, David M. Rissin, David C. Duffy, Sten Rubertsson, David H. Wilson, Kaj Blennow
Amyloid ß (Aß) peptides are proteolytic products from amyloid precursor protein (APP) and are thought to play a role in Alzheimer disease (AD) pathogenesis. While much is known about molecular mechanisms underlying cerebral Aß accumulation in familial AD, less is known about the cause(s) of brain amyloidosis in sporadic disease. Animal and postmortem studies suggest that Aß secretion can be up-regulated in response to hypoxia. We employed a new technology (Single Molecule Arrays, SiMoA) capable of ultrasensitive protein measurements and developed a novel assay to look for changes in serum Aß42 concentration in 25 resuscitated patients with severe hypoxia due to cardiac arrest. After a lag period of 10 or more hours, very clear serum Aß42 elevations were observed in all patients. Elevations ranged from approximately 80% to over 70-fold, with most elevations in the range of 3–10-fold (average approximately 7-fold). The magnitude of the increase correlated with clinical outcome. These data provide the first direct evidence in living humans that ischemia acutely increases Aß levels in blood. The results point to the possibility that hypoxia may play a role in the amyloidogenic process of AD.